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PERSPECTIVES IN CLINICAL NEPHROLOGY
Adhesion molecules in renal disease
Adhesion molecules are a heterogeneous class of ligands!
receptors that mediate cell adhesion, either to other cells or to the
extracellular matrix. Cell adhesion is of fundamental importance
to an impressive number of physiological and pathological pro-
cesses, including the differentiation of cells and their organization
in tissues [11, the intercommunication and activation of immune
cells [2], the recirculation and migration of white blood cells [3],
the growth and metastatic diffusion of tumoral cells [4]. On the
basis of molecular, structural and functional differences, adhesion
molecules have been separated into three main groups: the
integrins, the selectins and a group that belongs to the immuno-
globulin superfamily. In addition to these classic families of
adhesion molecules, a recently described family of chemoattrac-
tive cytokines, termed chemokines, behave as adhesion molecules
after having been released at a site of inflammation. These
ligands, in fact, bind to specific receptors in the endothelium or
extracellular matrix [5] and here regulate immune cell migration
by haptotaxis, a process driven by the gradient of adhesive ligands
affixed to the surface of cells or to the extracellular matrix [61.
This article first summarizes the features that distinguish the
families of adhesion molecules and gives a concise description of
their most relevant members. Then, the expression of adhesion
molecules in renal cells in culture and in normal renal tissue, and
the pathophysiological role of adhesion molecules in renal dis-
ease, with an emphasis on nephritis, transplant rejection and the
effects of hemodialysis on leukocytes will be reviewed.
Families of adhesion molecules
Integrin family
The name integrins was originally coined to signify the role of
these proteins in integrating the cytoskeleton with the extracellu-
lar matrix. Actually, integrins are very versatile and mediate both
cell-to-matrix and cell-to-cell adhesion. All integrins are mem-
brane glycoproteins consisting of two subunits, a larger alpha
chain and a smaller beta chain [4]. A classification in subfamilies
is based on the observation that some members have the same
beta chain but different alpha chain. Thus, we distinguish beta1
integrins (also called VLA, very late antigens, because some of
them appear on lymphocytes 2 to 4 weeks after antigen stimula-
tion) [7], beta2 integrins (called leukocyte integrins because of
their exclusive expression on leukocytes) [2] and beta3 integrins or
cytoadhesins [81. In the last few years, however, new beta chains
have been discovered, and it has been found that some alpha
subunits are linked to more than one beta subunit, making the
original classification insufficient [91.
All integrins conserve a strong sequence homology and struc-
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tural and functional similarity. Thus, the ligand binding site is
formed by short sequences on both chains [1]; the alpha chains
have three or four divalent cation-binding motifs [2], and the
intracytoplasmic domain interacts with the cytoskeleton through
an association with talin and, perhaps, other cytoplasmic proteins.
Many, but not all integrins recognize the specific amino-acid
sequence RGD (Arg-Gly-Asp) and synthetic peptides with this
sequence can block integrin-ligand interaction [2, 9].
The beta1 integrins are formed by the combination of the beta1
chain with different alpha chains and are numbered VLA-1 to
VLA-6 according to the alpha chain number (a1 to a6). They are
expressed on several cell types (leukocytes, platelets, fibroblasts,
epithelial cells and endothelial cells) and typically bind to extra-
cellular matrix proteins, mainly laminin, collagen and fibronectin.
Thus VLAs promote attachment of endothelial and epithelial
cells to substrata [9], adhesion of platelets to exposed subendo-
thelial matrix, tissue repair, and localization of leukocytes in
inflamed tissue [4]. Interesting and unusual is the behavior of
VLA-4, an integrin expressed on lymphocytes, morlocytes, ba-
sophils and eosinophils, that functions as a receptor for both
fibronectin and VCAM-1, a ligand of the immunoglobulin super-
family expressed on endothelial cells. VLA-4 therefore plays a
role in leukocyte-endothelial interactions.
The beta2 integrins consist of three members that are exclu-
sively expressed on leukocytes and are called LFA-1, Mac-I and
p150,95, respectively. LFA-i is found on virtually all immuno-
cytes, while Mac-i and p150,95 are predominantly expressed on
monocytes and granulocytes. These integrins are constitutively
expressed in a nonactive conformation. Cell activation is followed
by conformational change of the surface molecule and an increase
in the avidity of the receptor, as well as by rapid mobilization from
an intracellular pool and increased surface expression [10]. All
three beta2 integrins mediate adherence of leukocytes to endo-
thelium, a fundamental step in leukocyte migration. LFA-1 is the
best studied and, perhaps, the most important; its endothelial
ligands are two proteins of the immunoglobulin superfamily:
ICAM-1 and ICAM-2. In addition to endothelial cells, ICAM-1 is
induced by activation in several other cell types, including lym-
phocytes, monocytes, tissue macrophages and epithelial cells.
Thus, the interaction of LFA-1 with its counter-receptor ICAM-1
covers a broad range of immune cell contacts and functions
including antigen presentation, T-helper and B-lymphocyte re-
sponses, natural killing, and adherence of leukocytes to epithelial
cells [21.
The beta3 integrins are expressed on platelets, endothelium,
polymorphonucleates and monocytes. All bind fibrinogen and von
Willebrand factor, and some also bind fibronectin and vitronectin.
The member known as gp Jib/lila is the major integrin of platelets
where it binds soluble fibrinogen and von Willebrand factor.
These molecules work as multivalent ligands, that is, they bind to
other gp IIb/IIIa receptors on other platelets promoting platelet
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aggregation, or to receptors on endothelial cells or leukocytes,
causing adherence of platelets to these cells.
A number of integrins are formed with newly discovered beta
chains and are not as yet grouped in any subfamily. Some of them
are expressed on epithelium ()or on endothelium (ap5) and
play a role in cell attachment to matrix substrate.
Selectin family
The selectins are three surface glycoproteins characterized by a
similar structure consisting of an N-terminal lectin-like domain,
an epidermal growth factor (EGF) repeat, and a variable number
of modules homologous to complement binding proteins [11]. The
term selectin highlights the functional importance of the lectin
domain and the selectivity of distribution and function of these
molecules. The lectin domain plays a crucial role, of course,
containing the site that binds to specific carbohydrate counter-
receptors, but the EGF domain is likewise essential in mediating
adhesion. The role of the complement binding-like modules is less
defined, possibly involving the mechanical support that keeps the
lectin and EGF domains away from the cell surface. The selectins
are named according to the cell type on which they were originally
identified: E-selectin (endothelial cells), P-selectin (platelets) and
L-selectin (leukocytes). E-selectin expression is restricted to en-
dothelial cells activated by endotoxin or cytokines [12]. P-selectin
is found in both platelets and endothelial cells, where it is stored
in alpha and Weibel-Palade granules, respectively, in the resting
state [13], and is rapidly redistributed to the cell surface upon
activation by thrombin, histamine or other mediators [14]. L-
selectin is constitutively expressed on lymphocytes, neutrophils
and monocytes and is rapidly shed from their surface after cell
activation. All three selectins bind to one or more carbohydrate
ligands, mainly to sialyl-Lewis x and other fucosylated carbohy-
drates [15]. Counter-receptors of E-selectin are found on granu-
locytes, monocytes and a subpopulation of memory T-lympho-
cytes; P-selectin ligand is similarly distributed on leukocytes, and
L-selectin ligand is expressed on endothelial cells [15]. Thus, all
three selectins support the adhesion of leukocytes to endothelium,
a necessary step for leukocyte migration in inflamed tissue. The
adhesive reaction mediated by selectins is very quick, involving
small carbohydrate epitopes [16], and is of low affinity. It is now
clear that selectins play a role in the first step of leukocyte
migration, which consists of leukocyte rolling on the endothelial
surface and precedes the firm adherence mediated by integrins
[17]. In addition to being essential for leukocyte recruitment in
inflamed tissue, selectins regulate lymphocyte recirculation, that
is, the passage of lymphocytes from blood to tissue or lymph node
and then back to blood. Thus L-selectin functions as a "homing
receptor" (this term refers to receptors on lymphocytes, while the
counter-receptors on endothelium are called "addressins") for
peripheral lymph nodes, while E-selectin functions as addressin
for a subtype of memory lymphocytes [3].
Immunoglobulin superfamily
As previously discussed, the adhesion molecules of this group
are ligands of integrin receptors.
ICAM-1 and ICAM-2 (intercellular adhesion molecule-I and
-2), the counter-receptors of beta2 integrins, are closely related in
structure and function but differ in the number of Ig domains (5
and 2, respectively). ICAM-2 is constitutively expressed on endo-
thelial cells and its expression is not modified by stimulation; in
contrast, the constitutive expression of ICAM-1 on endothelial
cells varies in different vascular districts and is usually low.
Endothelial expression of ICAM-1, however, increases several
times after cell activation with IL-i, TNF or y-interferon [18]. In
addition to endothelial cells, other cell types express ICAM-1
after exposure to inflammatory stimuli, including leukocytes,
epithelial cells, dendritic cells, and fibroblasts. Thus the interac-
tion between beta2 integrins (mainly LFA-1) and ICAM-l regu-
lates leukocyte migration, the immune responses that depend on
adhesive contact between immune cells, and the binding of
leukocytes to epithelial cells and fibroblasts [2]. Circulating forms
of ICAM-1 were recently detected and their biological functions
are currently under investigation [19].
VCAM-1 (vascular cell adhesion molecule-i) is another adhe-
sion molecule of the immunoglobulin superfamily that contains
seven Ig domains. VCAM-i is induced by activation on endothe-
hal cells and supports the adhesion to endothelium of memory
lymphocytes [20] and other leukocytes expressing its beta1 inte-
grin counter-receptor VLA-4, that is, monocytes, basophils and
eosinophils. VCAM-1 is also expressed on several non-vascular
cell types, including dendritic cells in lymph node and skin, bone
marrow stromal cells and synovial cells [11].
Chemokines
The chemokines are a superfamily of polypeptides that are
characterized by the presence of four conserved cysteine (C)
residues. Two subfamilies are distinguished according to whether
another amino acid (X) is interposed between the first two C
residues (alpha or C-X-C subfamily), or whether these two C
residues are adjacent (beta or C-C subfamily). At present, fifteen
related chemokines have been described that are secreted by
different cell types such as platelets, white blood cells, endothelial
and epithehial cells, macrophages, and fibroblasts [21]. All chemo-
kines are chemoattractants, that is, they attract selected cell types
expressing receptors specific for them. Representative members
of the two subfamilies are interleukin-8 (C-X-C type) and
RANTES (C-C type), both of which play a relevant role in
inflammation by participating in leukocyte recruitment. These
chemokines function through a mechanism known as haptotaxis,
which makes them more similar to adhesion molecules than to
classic chemotactic factors. In fact, they do not diffuse freely away
from their site of production but bind to activated endothehium or
extracellular matrix, so that leukocyte migration occurs along the
gradient of chemokine affixed to the substratum. Leukocyte
receptors for chemokines are members of the G-protein-coupled
receptors and not only direct migration, but also activate integrin
adhesiveness and stimulate degranulation and the respiratory
burst. Their cellular distribution determines the responding cell;
thus, the IL-8 receptor is restricted to neutrophils, while the
RANTES receptor is expressed on monocytes, basophils, eosi-
nophils, and a subset of T lymphocytes with high reactivity to
recall antigens [22].
Renal expression of adhesion molecules
Adhesion molecules in cultured renal cells
Glomerular epithelial cells. Rat glomerular epithelial cells
(GEC) in culture constitutively express the beta1 integrins VLA-2
and VLA-3. These integrins mediate GEC adhesion to plastic
wells coated with extracellular matrix proteins (collagen I and IV,
laminin and fibronectin), and the adhesion is divalent cation
dependent, a function characteristic of integrins [23]. These
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observations suggest that beta1 integrins regulate in vivo GEC
attachment to glomerular basement membrane and play a role in
maintaining the normal architecture of the glomerular capillary
wall. It is of interest that the adhesion of rat GEC to collagen
induces responsiveness to epithelial growth factors and activates
phospholipase C [24], suggesting that the interaction of integrins
with extracellular matrix regulates not only adhesion, but also
GEC proliferation. Caution should be used, however, when
extrapolating these data to the in vivo condition, in which GEC
assume a unique shape with only the foot processes left in contact
with the basement membrane. Recent studies, in fact, have shown
that VLA-2 is not espressed in normal rat glomeruli, nor in GEC
newly isolated from glomeruli, but is synthesized ex novo by GEC
after several passages in culture, a phenomenon that probably
depends on loss of differentiation [25]. Accordingly, immunopre-
cipitation of GEC lysates with anti-alpha chain antibodies has
revealed only cs, that is, the alpha chain of VLA-3 [26]. VLA3
therefore appears to be the major or sole GEC integrin receptor.
Glomerular endothelial cells. In vitro rat glomerular endothelial
cells express beta1 integrins that mediate adhesion to components
of the glomerular basement membrane; in particular, in culture
conditions VLA-5 is the major fibronectin receptor, VLA-3 binds
type I collagen, and VLA-1 participates in adhesion to laminin
[27].
Mesangial cells. Human mesangial cells in culture use the
VLA-5 integrin receptor to bind to wells and beads coated with
fibronectin; interestingly, this VLA-5-mediated adhesion activates
phagocytosis of fibronectin-coated beads. [28]. Recently, mRNA
transcripts of integrin alpha chains 1, 2, 3 and 5 have been found
in cultured human and rat mesangial cells, and immunofluores-
cence analysis has revealed that their protein products are con-
centrated into focal adhesions, supporting their functional rele-
vance [29].
Murine mesangial cells express low constitutive levels of
ICAM-i and ICAM-1 mRNA transcripts. The expression of
ICAM-1 increases markedly after stimulation with INF-y and
TNF, and mesangial cells become capable of adhering to T lympho-
cytes and of presenting antigen; anti-ICAM-l mAb inhibits both
adhesion and antigen presentation [30].
Tubular cells. Beta1 integrins are expressed in primary cultures
of human renal tubular epithelial cells and contribute to cell
attachment to substratum; more precisely, VLA-5 binds tubular
cells to fibronectin, and VLA-2 and VLA-6 bind them to laminin
[31]. In addition to the ventral surface of cells, VLA-2 has also
been detected at intercellular borders, where it may function
during cell-cell interaction [32].
ICAM-1 was found to be constitutively expressed in over 90%
of human proximal tubular cells in an established primary culture.
ICAM-1 expression was up-regulated by supernatants from mixed
lymphocyte reaction and by recombinant cytokines, especially
INF-y, TNF-a and IL-i [33]. Adhesion of activated T lymphocytes
to human tubular cells in vitro is inhibited by antibody to ICAM-1
[34]. These findings suggest that ICAM-1 plays a critical role in
mediating lymphocyte adhesion to tubular cells.
VCAM-1 and its mRNA transcript are expressed in unstimu-
lated human tubular cells in primary culture, and their expression
is enhanced by stimulation with TNF-a [35]. Similar constitutive
VCAM-1 expression and up-regulation by cytokines occurs in
primary culture of mouse tubular cells; adhesion of homologous T
cells and monocytes layered on stimulated murine tubular cells is
inhibited by anti-VCAM-1 antibody [36].
Table 1. Expression of adhesion molecules in normal human kidney
Adhesion
Rena! expression
Interstitium
molecule Glomeruli Tubules and vessels
Integrins
VLA-1 Mesangium,
Bowman's capsule
All tubular
cells
NE
VLA-2 Endothelium Distal tubule NE
VLA-3 Mesangium
Visceral epithelium
Parietal epithelium
Endothelium
Distal tubule NE
VLA-5 Mesangium
Endothelium
NE NE
VLA-6 NE All tubules NE
LFA-t Monocyte/macrophage NE Monocyte/
macrophage
Ig superfamily
ICAM-1 Endothelium NE Vascular
endothelium
VCAM-1 Parietal epithelium Proximal
tubule
NE
Selectins
E-selectin NE NE Per itubular
capillaries
NE is not expressed.
RANTES mRNA transcript and its protein product are ex-
pressed in a culture line of proximal tubular cells of murine origin,
and the transcript level rises in response to stimulation with
TNF-n and IL-ia [37]. IL-8 has also been detected in human
renal epithelium [38]. These observations suggest that chemo-
kines released in vivo by inflammation-damaged tubular epithelial
cells may provoke or enhance the infiltration of leukocytes in
renal interstitium.
Adhesion molecules in normal kidney
The expression of adhesion molecules in normal human kidney
is summarized in Table 1.
Integrins. With the help of immunoelectron microscopy a
fibronectin receptor of the integrin beta1 subfamily was localized
early in human kidney, in the membranes of glomerular cells
facing the mesangial matrix and the glomerular basement mem-
brane [39]. Successive studies using monoclonal antibodies spe-
cific to single beta1 integrins have identified VLA-3 (a receptor
that binds fibronectin, laminin and collagen) as the predominant
VLA in the human glomerulus, where it is located in the
mesangium, Bowman's capsule and on the visceral epithelial and
endothelial cell surfaces in contact with the basement membrane.
The predominantly basal distribution of VLA-3 suggests that it
has a role in the attachment of glomerular endothelial and visceral
epithelial cells to glomerular basement membrane [28]. In other
studies, VLA-1 (receptor for laminin and collagen) was detected
in mesangium and Bowman's capsule, VLA-2 (receptor for lami-
nm) in glomerular endothelial cells, and VLA-5 (receptor for
fibronectin) in mesangium and glomerular endothelial cells [32,
40]. Beta1 integrins have also been isolated in proximal tubular
cells, where they are strictly basally confined, and in distal tubule
and ascending Henle's loop, where they are distributed both in a
sharp linear fashion basally and diffusely throughout the rest of
the cell membrane [41]. MoAbs directed against specific alpha
chains have demonstrated that the alpha6 chain, along with its
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corresponding beta1 integrin VLA-6 (laminin receptor), is con-
fined basally in all renal tubules, presumably anchoring epithelial
cells to the tubular basement membrane [42, 43], while VLA-2
and VLA-3 are restricted to the distal nephron [32]. VLA-l
(collagen receptor) is also expressed on the basal aspect of all
tubular cells [44].
In normal kidneys LFA-l expression is confined to isolated cells
throughout the interstitium and in the glomeruli. In the latter,
LFA-1 expressing cells number ito 10 per section and have been
identified by immunostaining with specific antibodies as mono-
cytes or migrating macrophages [34].
Immunoglobulin superfamily. The expression of ICAM-i in
normal human kidney has been the object of several studies [34,
35, 45, 46]. All agree that ICAM-i is constitutively expressed in
renal vascular endothelium, usually more intensely in interstitial
capillaries and venules than in arterial vessels and glomerular
capillaries. Most investigators have found no evidence of ICAM-1
expression in the mesangium, visceral glomerular epithelium,
renal tubules; however, weak mesangial expression has also been
described [47].
VCAM-1 is normally expressed on some parietal epithelial cells
in Bowman's capsule and parts of the proximal tubule, but it is not
constitutively expressed on visceral epithelium or endothelium
[35, 48]. It is interesting that VCAM-1 distribution in normal
kidney is complementary to that of the other immunoglobulin
ligand of integrin receptors, ICAM-1, suggesting some comple-
mentation of roles in renal pathophysiological conditions charac-
terized by the engagement of leukocytes.
Selectins. It has been reported that E-selectin is not detectable
in normal human kidney [35], or that it is occasionally expressed
in isolated peritubular capillaries [49]. The carbohydrate ligand of
L-selectin, sLe", has been shown in small amounts in normal rat
glomeruli [50].
Chemokines. The only study on distribution of RANTES in
"normal" human kidney has been performed in renal biopsy
samples of transplanted kidneys taken one hour after vascular
anastomosis during transplantation surgery; in these kidneys
neither RANTES nor its mRNA transcript were expressed [511.
The changes in adhesion molecules associated with renal
disease are summarized in Table 2.
Adhesion molecules in nephritis
Changes in renal disease
Adhesion molecules (interested cell or site)
S Heymann nephritis (podocyte)
5 "new" models of NTN (podocyte)
anti-thymocyte serum nephritis (glomeruli)
ischemic/toxic acute renal failure (tubular
cells)
, membranous nephropathy (glomerular
capillary)
¶ IgA nephropathy (mesangium)
hemodialysis (peripheral leukocytes)
b renal carcinoma (tumoral cells)
1' "classic" NTN (glomerular and interstitial
capillary endothelium, interstitial resident
cells)
murine lupus nephritis (mesangium,
proximal
tubule, vascular endothelium)
focal glomerulosclerosis (mesangium)
¶ extracapillary glomerulonephritis (cellular
crescents, tubules)
¶ human lupus nephritis (glomeruli, tubules)
membranous nephropathy (glomerular
capillary endothelium)
¶ "active" nephritides (tubules)
1' acute and chronic rejection (tubules)
J. hemodialysis (peripheral leukocytes)
¶ "classic" NTN (glomerular capillary
endothelium)
¶ murine lupus nephritis (mesangium,
proximal tubule)
¶ glomerulonephritides and noninflammatory
glomerular diseases (diabetes, gout and
amyloid nephropathy) (proximal tubule)
¶ acute rejection (vascular endothelium,
tubules, dendritic interstitial cells)
¶ cryoglobulinemia (glomerular capillary wall)
¶ acute rejection (tubular cells,
peritubular capillary endothelium)
¶ "classic" NTN (glomerular capillary
endothelium)
¶ hemodialysis (peripheral leukocytes)
Experimental models: Heymann nephritis and nephrotoxic serum
nephritis. In classic passive Heymann nephritis (HN), proteinuria
occurs when anti-Fx1A antibodies raised against a proximal
tubular antigen cross react with antigens on glomerular visceral
epithelial cells (GEC) and gradually accumulate in the subepithe-
hal space, leading to activation of complement and proteinuria in
four to five days [52]. Proteinuria, however, can also be induced in
24 hours by injecting F(ab)2 or F(ab)' fragments of anti-Fx1A
antibody, which do not activate complement [53]. This rapid-
onset, complement-independent proteinuria is transient and as-
sociated with fine subepithelial deposits and a characteristic
morphologic alteration consisting of effacement of GEC foot
processes. Clearly the lesion produced by F(ab) fragments differs
from that of classic HN. Adler and Chen recently showed that
anti-Fxl A antibody recognizes the VLA-3 integrin receptor on
GEC in culture. In their study, anti-Fx1A inhibited the adhesion
of GEC to several substrata and produced reversible cell detach-
ment and "rounding up" when added to adherent cells [54]. These
results suggest that the binding of anti-Fx1A or its F(ab) frag-
ments to the main integrin receptor of podocytes may alter the
normal adhesion of GEC to GBM and cause cell detachment,
which is responsible for altered glomerular permeability and
proteinuria. The different disease courses caused by whole anti-
body and F(ab) fragments depend on differences in size and
ability to activate complement. Due to their small size, F(ab)
fragments are able to accumulate rapidly in the subepithelial
space and in a short time produce a transient proteinuria,
transient because it is not sustained by the inflammatory cascade
initiated by complement activation.
Nephrotoxic serum nephritis (NTN) is a model of nephritis
induced in rat by injecting heterologous anti-kidney antiserum. In
classic NTN renal injury is both complement- and leukocyte-
dependent and is caused by antibodies directed against antigens in
the GBM. In the last few years, however, it has become clear that
Table 2. Adhesion molecules in renal disease
Intergrins
13 integrins
132 integrins
01, 06, a subunits
Ig superfamily
ICAM-1
VCAM-1
Chemokines
RANTES
Selectins
E-selectin
Pathogenic role of adhesion molecules in renal disease L-selectin
Symbols are: ¶ upregulation, ¶ downregulation, 1 dysfunction. Changes
found in human diseases are indicated in bold.
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nephrotoxic sera are polyreactive, that is, they contain antibodies
directed against several cell-surface antigens in addition to the
classic GBM antigens [55]. Furthermore, it has been shown that
some of these antibodies can cause proteinuria directly, in the
absence of complement activation or inflammatory cell infiltrates.
Several new models of NTN have thus been designed [56, 57] that
are clearly different from classic inflammatory NTN. In these
models of NTN a characteristic morphological correlate of pro-
teinuria is effacement and detachment of podocytes from GBM,
so that it is reasonable to speculate that antibodies interfere with
normal podocyte-GBM adhesion. Early evidence that podocytes
might be the target of antiserum in complement-independent
NTN was given by the demonstration that a monoclonal antibody
against the epithelial surface antigen SGP-1151107 can directly
induce both proteinuria and the characteristic, structural alter-
ations [58]. Recently, O'Meara and coworkers have shown that a
non complement-binding anti-rat nephrotoxic serum reacts with
surface antigens of GEC. This antiserum immunoprecipitates two
proteins from GEC that are co-precipitated by a monoclonal
antibody identifying the beta1 integrin receptor for fibronectin. In
addition, in culture the antiserum inhibits adhesion of GEC to
collagen, laminin and fibronectin, and prevents GEC spreading on
a variety of matrix proteins [59]. These findings suggest that
anti-integrin antibodies disrupt GEC anchorage to GBM and thus
cause detachment of foot processes and alteration of glomerular
capillary permeability.
In summary, modifications of two classic models of nephritis
have led to the development of models of antibody-dependent,
complement-independent renal injury characterized by rapid-
onset proteinuria, alterations of podocyte morphology (efface-
ment of foot processes), and detachment of epithelial cells from
the basement membrane. Interference with the normal anchorage
of GEC to GBM caused by antibodies to integrin receptors on
podocytes seems to be the common pathogenic mechanism in
these models. It is reasonable to speculate that similar interfer-
ences with integrin function, caused by toxic substances or circu-
lating factors, may play a pathogenic role in other models of
non-inflammatory proteinuria, for example, puromycin nephrosis
or human minimal change nephropathy.
Recent studies have shown that leukocyte adhesion molecules
and their endothelial ligands also play a fundamental pathogenic
role in classic NTN caused by anti-GBM antibodies. Infusion of
anti-GBM antibodies, in fact, is followed by up-regulation of
E-selectin, ICAM-i and VCAM-i on glomerular capillary endo-
thelium. Leukocyte recruitment in glomeruli and proteinuria is
inhibited by treating rats with antibodies against ICAM-l and
VCAM-l, and their counter-receptors LFA-l, Mac-i and VLA-4.
Protection is also afforded by anti-TNF-a antibodies, suggesting
that this cytokine, perhaps released locally, is responsible for
up-regulation of endothelial adhesion molecules [60—62]. In the
early phase of anti-GBM nephritis, ICAM-i is strongly up-
regulated in the endothelium of interstitial capillaries as well and
is expressed de novo in interstitial resident cells. ICAM-1 there-
fore appears to direct migration and localization of interstitial
leukocytes [63].
Other models of nephritis. Wuthrich et al studied the renal
expression of ICAM-1 and VCAM-1 in murine models of lupus
nephritis. With the aid of immunoperoxidase staining they showed
a strong up-regulation of ICAM-1, in particular in the brush
border of proximal tubules, in the mesangium and in the endo-
thelium of large vessels. Northern analysis revealed a two- to
fivefold increase in the levels of ICAM-1 transcripts in the kidney
of nephritic mice [64]. Like ICAM-1, VCAM-1 was up-regulated
in cortical tubular and mesangial cells, but the tubular expression
of VCAM-1 was more focal, being localized in tubules adjacent to
mononuclear infiltrates. Adherence assays on kidney sections
from autoimmune rats showed an increased adhesiveness of T cell
and macrophage cell lines and of lymph node cells that was
inhibited by monoclonal antibodies targeting the ICAM-1 and
VCAM-1 molecules [36]. These results indicate that enhanced
ICAM-1 and VCAM-1 expression confers increased adhesiveness
on the renal parenchyma in lupus nephritis and serves as a
pathway by which inflammatory cells adhere to renal tissue and
promote renal injury.
Injection of anti-thymocyte serum produces an acute form of
glomerulonephritis in the rat characterized by transient mesangi-
olysis, followed by mesangial cell activation and mesangial matrix
synthesis that is promoted by increased local activity of TGF-f3
[65]. Recent studies have shown that the increased matrix depo-
sition in this glomerulonephritis is associated with over-expression
of glomerular beta1 integrins VLA-1 and VLA-5 and reduced
expression of VLA-3. In in vitro studies, normal glomeruli treated
with TGF-p showed changes in integrin expression mimicking
those occurring in vivo. These results suggest that the proliferative
effect of TGF-13 is mediated by altered beta1 integrin expression
[66].
Human nephritis. Seron et al studied the expression of VCAM-1
in renal biopsies from patients with interstitial nephritis due to
NSAID, systemic vasculitis with crescentic nephritis, and other
forms of inflammatory and non-inflammatory glomerular disease
(IgA, membranous, minimal change, diabetes, lupus, gout and
amyloid nephropathy). Proximal tubular expression of VCAM-1
was elevated in all such disorders, but the increase was especially
marked in vasculitis and interstitial nephritis. VCAM-1 expression
was positively correlated with the number of activated (trans-
ferrin-receptor positive) leukocytes infiltrating the interstitium.
Surprisingly, VCAM-1 was never identified on vascular endothe-
hum [48]. Up-regulation of VCAM-1 was also found in different
forms of glomerulonephritis by Bruijn and Dinklo [67]. These
authors documented increased expression on proximal tubules
and on the endothelium of large interstitial vessels, but not on
interstitial capillaries, in all the diseases studied (membranous
and membranoproliferative glomerulonephritis, IgA nephropa-
thy, lupus nephritis, cryoglobulinemia, Wegener's disease). Par-
ticularly strong expression of VCAM-1 in the glomerular capillary
wall was observed in cryoglobulinemia. These findings suggest
that VCAM-1 plays a pathogenic role in several renal diseases by
promoting an interaction between inflammatory and tubular
epithelial cells. Such interaction may be necessary for the mono-
nuclear cell cytotoxic attack, as well as for the tubular cell
accessory function as antigen presenting cell.
The author and his coworkers have studied the expression of
ICAM-l in primary focal segmental glomeruloscierosis (FSGS),
membranous nephropathy (MN), necrotizing glomerulonephritis
(NGN) with crescent formation, and lupus nephropathy. We have
shown intense de novo expression of ICAM-1 on mesangial cells in
FSGS, with focal and segmental distribution, but no up-regulation
of the molecule in MN [43]. While the pathogenic role of ICAM-1
in FSGS remains to be established, the increased mesangial
expression of this molecule clearly indicates activation of mesang-
ial cells and suggests an inflammatory step in the progression of
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the disease. Interestingly, we recently found that ICAM-1 is ex-
pressed de novo in the mesangium of patients with minimal change
disease, similar to what occurs in patients with FSGS (Dal Canton
and Meyrier, unpublished observations), which supports the con-
tention that the two diseases are but two sides of the same coin.
We also discovered abnormal expression of ICAM-1 in the
glomeruli of patients with crescentic glomerulonephritis. In fact,
ICAM-1 was strongly expressed in cellular crescents, a finding that
suggests a role for this molecule in recruiting macrophages in the
early stage of the disease [68]. Increased glomerular expression
was a marker of activity in lupus nephritis [691, Other studies have
shown altered renal expression of ICAM-1 in different forms of
glomerulonephritis. Lhotta et al observed increased glomerular
expression in early cases of rapidly progressive glomerulonephritis
and in lupus nephritis, while the expression was reduced in
advanced rapidly progressive glomerulonephritis and membra-
nous nephropathy. Increased ICAM-1 expression was also de-
tected on tubular cells in rapidly progressive glomerulonephritis
and membranoproliferative glomerulonephritis [45]. Tubular ex-
pression of ICAM-1 was studied by Chow et al in renal biopsy
specimens from a range of non-immune renal diseases and
glomerulonephritides. Increased tubular expression of ICAM-1
was found on undamaged tubules in glomerulonephritis and this
showed a strong correlation with disease activity [70]. In summary,
ICAM-1 seems to play a role in promoting glomerular recruit-
ment of leukocytes and extracapillary proliferation in exudative
and crescentic glomerulonephritis, respectively; in addition, in
several other forms of nephritis, de novo expression of ICAM-1 on
tubular cells confers them a stickiness for adhesive contact with
infiltrating leukocytes whose toxic attack may thus be facilitated.
Baraldi and coworkers studied the expression of integrin
VLA-3 in renal biopsy specimens from patients with nephrotic
syndrome due to membranous nephropathy (MN), minimal
change disease and lupus nephritis [71]. It is noteworthy that the
normal linear distribution of VLA-3 along the glomerular capil-
lary loop was altered in membranous nephropathy but not in the
other diseases, indicating that changes in MN were not an
aspecific effect of proteinuria. In stages I and II of MN, VLA-3
distribution showed an irregular, trabecular pattern; in addition,
in stage III a segmental loss of VLA-3 was detected [71]. These
observations suggest that in human MN, as in its experimental
counterpart (Heymann nephritis), a disruption of the normal
interaction between VLA-3 and its GBM ligand occurs.
Recently, the expression of fibronectin receptor (assumed to be
an integrin) was found to be elevated in the mesangium of
patients with IgA nephropathy. This increase was correlated with
the degree of histological glomerular damage and proteinuria
[72]. The pathophysiological relevance of this observation is not
clear, but one may speculate that up-regulation of the fibronectin
receptor plays a role in the activation of mesangial cells that is the
hallmark of this disease.
Adhesion molecules in renal transplant
Pathogenic role of adhesion molecules in graft rejection. Cell-
mediated rejection is an immune reaction characterized by the
migration of mononuclear cells into renal tissue and by an effector
response driven by the interaction between MHC molecules on
donor cells and TCR on recipient T cells. Since both adherence of
leukocytes to endothelium (which is crucial for leukocyte migra-
tion) and stabilization of the TCR-antigen interaction (necessary
for full T cell activation) are mediated by adhesion molecules, it is
logical to expect that adhesion molecules play an important
pathogenic role in rejection. Until now the interest of investiga-
tors has been mainly limited to evaluating renal expression of
ICAM-1 in acute and chronic rejection [34, 35, 46, 49, 73—75]. All
agree that graft rejection is accompanied by de novo expression of
ICAM-1 on renal tubular cells. Such expression is predominant in
the proximal tubules and has a focal distribution occurring in 15 to
40% of tubules. It is paralleled by up-regulation of HLA class II
antigens and is roughly proportional to the level of leukocyte
infiltration. The de novo tubular expression of ICAM-1, however,
is not specific to graft rejection, since it has also been found in
non-rejecting kidneys [49] and may depend on ischemic damage
during organ retrieval [46]. Increased ICAM-1 expression on
renal vascular endothelium has occasionally been described dur-
ing rejection [46], but this finding is inconsistent, mainly because
ICAM-1 is constitutively and diffusely expressed on normal renal
endothelium as well [34, 491. In summary, these studies suggest
that in renal graft rejection significant de novo ICAM-1 expression
on tubules supports the contact between tubular cells and infil-
trating leukocytes. In this way, both the antigen presentation by
tubular cells (in the context of class II MHC molecules) and the
cytotoxic attack of effector cells are facilitated. A role for ICAM-1
in the recruitment of leukocytes into renal tissue has not definitely
been proven, and renal expression of ICAM-1 cannot be used to
discriminate rejection from other causes of acute graft dysfunc-
tion. An attempt has been made to utilize serum levels of
circulating ICAM-1 or ICAM-1 expression on renal tubular cells
present in urinary sediment as diagnostic indicators of acute
rejection, but with poor success [75, 76]. In fact, circulating
ICAM-1 concentration increases not only during rejection but
also during cytomegalovirus infection, and cells expressing
ICAM-1 are found in the urine of both rejecting and non-rejecting
patients.
A number of studies have recently investigated the expression
of other adhesion molecules in renal graft rejection. In acute
rejection de novo expression of VCAM-1 is induced on renal
vascular endothelium, and the expression of this molecule is
up-regulated in the tubules [35, 49, 73, 74]. Dc novo VCAM-1
expression is particularly pronounced on the endothelium of
muscular arteries showing features of acute vascular rejection,
that is, endothelial separation from the underlying intima and
subendothelial infiltration of mononuclear cells. In acute vascular
rejection VCAM-1 is also found on a distinct population of
dendritic cells within interstitial lymphoid aggregates, and focally
on mesangial cells [77]. These results suggest that VCAM-1 plays
a double pathogenic role in renal graft rejection by (a) potentiat-
ing the interaction between tubular cells and effector cells, and (b)
promoting leukocyte migration into renal tissue. Dc novo induced
expression on renal endothelium is particularly relevant and
seems to be a distinctive feature of rejection that is useful for
differentiating acute rejection from other causes of graft dysfunc-
tion, for example, cyclosporine toxicity [73].
Only a few studies have examined E-selectin in renal allograft
rejection in humans, and no change in its expression was detected
[49, 74]. E-selectin, however, is induced early and transiently in
inflammatory response so that grafts may have been biopsied after
the level of E-selectin had declined. A role for L-selectin and its
sialyl Lewis' ligand in determining the site of lymphocyte extrav-
asation into the graft has recently been shown in a rat model of
acute renal graft rejection [50].
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The role of the RANTES chemokine in cell-mediated trans-
plant rejection was recently defined in elegant studies by Pattison
et a! [49]. These authors demonstrated that during rejection both
RANTES and RANTES mRNA are expressed by infiltrating
mononuclear cells and by renal tubular cells. In addition, they
localized RANTES protein (but not mRNA) on the endothelium
of peritubular capillaries and showed that RANTES receptors are
expressed on this endothelium. These results allow construction
of a model of the central role played by RANTES in transplant
rejection. Macrophages in the graft produce cytokines that acti-
vate the expression of RANTES by renal tubular epithelium.
RANTES released by tubular cells diffuses locally and binds to
receptors on endothelial cells. After being planted on the endo-
thelium RANTES works as an adhesion molecule, attracting T
cells and monocytes to the site of inflammation, and once these
cells have entered the interstitium they are driven to their target
by the RANTES gradient expressed on tubular cells.
Anti-rejection therapy with anti-adhesion molecule mAbs. An
anti-LFA-1 monoclonal antibody was first used successfully to
prevent graft failure in children with HLA-mismatched bone
marrow transplants [78]. The same antibody (murine mAb 25-3)
was then used to treat seven subjects with acute renal graft
rejection. Only one patient, who had the lowest increase in blood
creatinine, reverted to pre-rejection graft function with 25-3
treatment alone. All the others required additional rescue ther-
apy, so it was concluded that anti-LFA-1 is inefficient in reversing
acute ongoing renal rejection. Treatment with 25-3 caused a
reversible side effect (Quincke's edema) in only one patient and
did not raise anti-murine antibodies in any case [79]. These
results, while disappointing, do not exclude the possibility that the
antibody may be more useful for preventing renal graft rejection
(as in bone marrow transplantation) than for treating rejection
episodes in course.
The effects of blocking ICAM-1 were first studied by Cosimi et
al in cynomolgus monkeys [801. These authors administered a
murine anti-ICAM-1 mAb (R6.5) as the sole agent to prevent
rejection in a group of animals and used R6.5 to treat ongoing
acute rejection in another group maintained on cyclosporine.
Treatment with the antibody significantly prolonged survival in
the first group and reversed rejection in all animals of the second
group. These results encouraged Haug et a! to use the same
antibody in a phase I trial in human renal allograft recipients.
Eighteen patients who received allografts at high risk for delayed
graft function received doses of R6.5 in order to maintain
adequate serum levels (>10 Wml) for a two-week course. The
patients treated with anti-ICAM-1 mAb had significantly fewer
delayed graft function and rejection episodes than a group of
patients who received the contralateral kidney from the same
donor and conventional treatment. In addition, none of the
anti-ICAM-1 treated patients developed primary non-function, in
contrast with 3 out of 18 in the control group [81]. Therapy with
R6.5 was well tolerated.
In conclusion, preliminary results indicate that anti-ICAM-1,
but not anti-LFA-1 therapy, may be useful in treating acute renal
graft rejection. Why blocking ICAM-1 is efficient but blocking its
ligand is not remains unclear. A possible explanation is that
anti-LFA-i operates only on leukocytes, while anti-ICAM-1 can
also act at the target cell level. Part of the benefit displayed by
anti-ICAM-1, however, may result from a protective effect on
reperfusion injury.
Effects of extracorporeal hemodialysis on leukocyte adhesion
molecules
Hemodialysis causes a profound, transient neutropenia whose
possible mechanisms include leukocyte aggregation, adhesion to
endothelia, and pulmonary sequestration [82]. There is evidence
that dialysis-related neutropenia depends on complement activa-
tion and generation of the complement fragments C3a and C5a,
which can activate leukocytes [83]. Arnaout et al first demon-
strated a rapid up-regulation of the granulocyte beta2 integrin
Mac-i during dialysis with cellulose filters [84]. Interestingly, the
time course of increased expression of this receptor coincided
with the development of granulocytopenia and with the peak rise
in plasma levels of the complement activation products C5a
desArg and C3a desArg. C5a desArg (but not C3a desArg)
induced a comparable increase in Mac-i expression on normal
granulocytes in vitro at concentrations similar to those measured
in vivo. The overexpression of Mac-i during cuprophane dialysis
was confirmed by Alvarez et a!, who also found that dialysis
increased leukocyte expression of p 150,95, another beta2 integrin,
and down-regulated the expression of L-selectin. Similar pheno-
typic changes were reproduced in vitro by incubating neutrophils
with activating agents. Kinetic studies showed that both the peak
increase in integrin expression and the maximal drop in L-selectin
expression occurred after iS minutes of dialysis, coincident with
the nadir in neutrophil count. Neither neutropenia nor the
changes in leukocyte adhesion molecules took place when hemo-
dialysis was performed with polyacrylonitrile membranes [82].
The ability of cuprophane membranes to activate serum directly
was proved by Lundahl, Hed and Jacobson, who showed that
serum preincubated with fragments of cuprophane membranes
increased Mac-i expression on normal leukocytes [85]. The causal
relation between complement activation and changes in leukocyte
adhesion molecules during hemodialysis was further confirmed by
Himmelfarb et a! [86], who utilized either first-use cellulose
dialyzers (that activate complement) or reused dialyzers (that
have minimal complement activating potential). First use dialyz-
ers, but not the reused ones, caused a rapid, fourfold increase in
Mac-i and a twofold decrease in L-selectin. Stimulation of
granulocytes in vitro with C5a reproduced the same changes seen
in vivo. Taken together, these results demonstrate that dialysis
with cellulosic membranes causes complement activation and
generates complement products that can activate leukocytes.
Leukocyte activation is associated with changes in the expression
of adhesion receptors that are responsible for leukocyte seques-
tration and leukopenia. Himmelfarb et a! also performed adhe-
sion assays of leukocytes on monolayers of human umbilical
endothelial cells [86]; the ability to adhere leukocytes with the
"high Mac-I, low L-se!ectin" phenotype, harvested from patients
during dialysis, was dramatically decreased. This intriguing finding
may be explained by the rapid dialysis-induced transformation of
granulocytes into a "refractory" post-activation state, in which
shedding of L-selectin caused by activation [ii] prevents adhe-
sion. Preliminary results suggest that other changes in surface
adhesion molecules caused by dialysis, such as reduced ICAM-i
expression [87], account for the loss of the adhesive capacity of
leukocytes and thus may contribute to the increased susceptibility
to infection of dialysis patients.
Another leukocyte dysfunction caused by hemodialysis is de-
granulation of peripheral blood neutrophils. Degranulation oc-
curs mainly, but not exclusively, with cuprophane membranes and
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is an untoward phenomenon that participates in the pathogenesis
of the catabolic state and of the carpal-tunnel syndrome, which
are frequently observed in dialysis patients [88, 891. Recently,
Cheung et al [89] have shown that products generated by the
contact of plasma with the cuprophane membranes are responsi-
ble for degranulation. These products have not been precisely
identified but are in part complement dependent, in part comple-
ment independent. In any case, they act on leukocytes through a
common pathway that consists of beta2 integrins. In fact, unlike
normal leukocytes, those harvested from a patient with a congen-
ital deficiency of beta2 integrins do not degranulate when incu-
bated with plasma and cuprophane membrane.
In summary, the present information indicates that adhesion
molecules mediate leukocyte dysfunctions caused by hemodialy-
sis. Therefore the effects of different dialysis membranes on
leukocyte adhesion receptors should be taken into account as an
important index of biocompatibility.
Adhesion molecules and other renal disorders
Acute renal failure. Obstruction of renal tubules by desqua-
mated cells and debris plays an important pathogenic role in
post-ischemic and nephrotoxic acute renal failure [90, 91]. Recent
studies have shown that the majority of cells desquamated after
renal insults are viable, suggesting that active cell aggregation may
contribute to the development of tubular obstruction [921. In
addition, it has been found that oxidant stress to renal epithelia
results in the disruption of focal contacts, the disappearance of
talin from the basal cell surface (talin is a cytoskeleton protein
connected with the intracellular part of integrin receptors), and a
redistribution of the alpha1 integrin subunit from its predomi-
nantly basal location to the apical cell surface. These changes are
associated with decreased adhesion of tubular cells to wells coated
with type IV collagen, laminin, fibronectin and vitronectin [931
The ectopically expressed apical integrins, however, are function-
ally competent and capable of mediating cell-cell adhesion in cell
suspensions [94]. Based on the above observations, the following
scenario has been hypothesized for the development of tubular
obstruction secondary to tubular cell insult: the loss of basolateral
expression of integrins is responsible for the detachment of cells
from the matrix, whereas the expression of integrin receptors on
the apical surface accounts for facilitated cell-cell adhesion and
eventual tubular obstruction [95] This hypothesis is supported by
the observation that infusion of an integrin inhibitor in rats
subjected to renal ischemia prevents a rise in intratubular pres-
sure, the pathophysiological marker of tubular obstruction [94].
Renal cysts. Renal cyst formation derives from abnormal tubular
cell proliferation and is accompanied by abnormalities in the
synthesis of matrix by cyst-lining cells [96] and changes in epithe-
hal polarity [97]. It is known that epithelial cells are responsible
for the composition of their basement membranes, and the
basement membrane in turn modulates cell movement, division,
differentiation and polarity. As discussed previously, tubule cell-
matrix interactions are mediated by adhesion receptors, mainly of
the integrin family. It is not surprising, therefore, that preliminary
results indicate that members of the beta1 integrin family are
involved in the dysregulation of the epithelial polarity that occurs
in a model of in vitro cyst formation [98]. A role for attenuated
expression of epithelial cell adhesion molecules has been sug-
gested in a murine model of polycystic kidney disease [99].
Renal cell carcinoma. Integrin distribution has been studied in
renal cell carcinomas of various grades of malignancy [100]. The
alpha3 subunit was detected in all tumors regardless of the grade
of malignancy. This finding is interesting because renal cell
carcinomas are believed to originate from both proximal and
distal tubular cells, while in normal kidney alpha3 expression is
restricted to the distal tubule. The alpha6 subunit was expressed in
low-grade malignancies, in which it coaligned with basement
membrane components expressed in the matrix. In contrast, the
alpha6 subunit was absent in G3 carcinomas, reflecting a complete
disruption of cell-basement membrane interaction and, possibly,
metastatic invasiveness. Noteworthy was the de novo expression of
alpha chain, which is not present in normal kidney and is
correlated with the degree of malignancy. In summary, these
results indicate that changes in integrin expression are associated
with malignant transformation of cells in renal carcinoma and may
play a role in their metastatic diffusion.
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